加载中
NASDAQHealthcareBiotechnology
最新数据
US$6.567
−US$0.203 · -3.00%
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
常规交易时段
US$6.567
−US$0.203 · -3.00%
盘中时间采用ET。市场数据可能有所延迟。
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
日内区间
当前US$6.567
52周区间
当前US$6.567
盘中时间采用ET。市场数据可能有所延迟。
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
日内区间
当前US$6.567
52周区间
当前US$6.567
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 25.1万 USD | 3349.2万 USD | 493.1万 USD | 200.2万 USD |
| 销货成本 | 259.7万 USD | — | — | — | — |
| 毛利 | −259.7万 USD | 25.1万 USD | 3349.2万 USD | 493.1万 USD | 200.2万 USD |
| 研究与开发 | 6954万 USD | 5032.8万 USD | 5025.1万 USD | 4398.4万 USD | 4241万 USD |
| 销售、一般及管理费用 | 2027万 USD | 1720.5万 USD | 1391.2万 USD | 2077.6万 USD | 1286.4万 USD |
| 营业费用 | 8801.3万 USD | 6753.3万 USD | 6416.3万 USD | 6476万 USD | 5527.4万 USD |
| 利息收入 | 595.9万 USD | 534.9万 USD | 253.5万 USD | 129.4万 USD | — |
| 折旧和摊销 | 259.7万 USD | 243.1万 USD | 226.6万 USD | 115.8万 USD | 24.8万 USD |
| 营业利润 | −9061万 USD | −6728.2万 USD | −3067.1万 USD | −5982.9万 USD | −5327.2万 USD |
| 净利润 | −8386.5万 USD | −5849.3万 USD | −2769.6万 USD | −5838.8万 USD | −7182.5万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$37.50
上涨空间 471.04%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI790.89万0.00%2.3万亿 USD0.03%US$381.07-0.13%
iShares Russell 2000 ETFIWM322.75万0.00%787.4亿 USD0.19%US$276.63-0.46%
Vanguard Extended Market ETFVXF304.14万0.00%954亿 USD0.05%US$232.47-0.45%
iShares Russell 2000 Value ETFIWN99.76万0.01%137.49亿 USD0.24%US$210.41-0.32%
Simplify Propel Opportunities ETFSURI68.62万0.91%7606.44万 USD2.82%US$17.2565-0.02%
iShares Micro-Cap ETFIWC40.88万0.03%13.17亿 USD0.60%US$180.67-0.55%
iShares Russell 2000 Growth ETFIWO33.52万0.00%139.17亿 USD0.24%US$351.55-0.61%
Franklin Small Cap Enhanced ETFFSML30.69万0.20%1.5亿 USD0.45%US$28.8585-0.01%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNSimplify Propel Opportunities ETFSURIiShares Micro-Cap ETFIWCiShares Russell 2000 Growth ETFIWOFranklin Small Cap Enhanced ETFFSMLAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
